Skip to main content
. Author manuscript; available in PMC: 2013 Jun 10.
Published in final edited form as: Hepatology. 2011 Jun 27;54(2):749. doi: 10.1002/hep.24310

Figure 1.

Figure 1

Representative serum HCV RNA decline from baseline during the first week of treatment with silibinin monotherapy6 (red squares), RG7128 1500-mg BID (blue circles; manuscript in preparation), daily 10MIU IFN9 (black triangles) and telaprevir+PegIFN8 (gray triangles). Solid lines were used to emphasize plausible phases of viral decline.